Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic data of cord blood CD34+ cells as controls of transcriptome cohort of pediatric acute myeloid leukemia

ABSTRACT: We established a transcriptome cohort of pediatric acute myeloid leukemia (n=553) with RNA sequencing. This dataset of cord blood CD34+ cells (n=5, indivisual lots) is normal controls to characterize leukemia-specific expression patterns.

ORGANISM(S): Homo sapiens

PROVIDER: GSE190269 | GEO | 2022/02/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic data of cord blood CD34+ cells as controls of transcriptome cohort of pediatric acute myeloid leukemia

Project description:Transcriptomic data of cord blood CD34+ cells as controls of transcriptome cohort of pediatric acute myeloid leukemia

| PRJNA786561 | ENA

Expression data from cord blood CD34+ cells transduced with UBTF wildtype expression vectors, UBTF-TD expression vectors, or empty control vector.

Project description:UBTF tandem duplications (UBTF-TD) were identified frequently in relapsed pediatric acute myeloid leukemia. The purpose of this study is to investigate the functional consequence of the overexpression of UBTF-TD in normal cord blood CD34+ cells.

2022-02-22 | GSE189901 | GEO

AML1-ETO transduced human cord blood cells, CD34 selected, compared to normal cord blood cells, CD34 selected

2007-12-20 | GSE8023 | GEO

Transcription profiling of human AML1-ETO transduced cord blood cells, CD34 selected, compared to normal cord blood cells, CD34 selected

Project description:AML1-ETO expression in normal human umbilical cord blood CD34+ cells leads to long-term proliferation of an early self-renewing primitive progenitor cell with multilineage potential and stem cell ability, but these cells do not induce leukemia in immunodeficient mice. This comparative microarray study was initiated to determine the differences in the transcriptome of AML-ETO-expressing CD34+ cells after extended culture in vitro, using normal cord blood cells expanded for 6-8 weeks in vitro and subsequently purified for the CD34+ population as the control comparison. Experiment Overall Design: We have established a culture system whereby we retrovirally transduce human CD34+ cells, obtained from cord blood, with the leukemia fusion gene AML1-ETO. Cells expressing this fusion protein are able to proliferate long-term in vitro in a cytokine dependent manner. AML1-ETO-expressing cord blood cells have a large population of primitive self-renewing CD34+ cells with continued abnormal differentiation. We grow these cells in serum-free conditions using the BIT supplement from Stem Cell Technologies. For the current experiments we used cell cultures that had been proliferating in vitro for 8-12 weeks, in a cytokine cocktail of SCF, TPO, FLT3L, IL-6 all at 20 ng/mL and IL-3 at 10 ng/mL. Control cord blood samples that were CD34 purified were expanded for 5-8 weeks in the same culture media as used for AML1-ETO cells. All samples were magnetically selected for the CD34+ population, returned to culture, and one week later again selected for CD34+ cells and then lysed for RNA isolation.

2008-06-15 | E-GEOD-8023 | biostudies-arrayexpress

Lin-CD34+ cord-blood cells

Project description:Lin-CD34+ cord-blood cells

| PRJNA754146 | ENA

Highly purified human cord blood-derived CD34+/- hematopoietic stem cells

Project description:Global gene expressions of human cord blood-derived 18Lineage-negative (18Lin-)CD34+CD38-CD133+GPI-80+ cells (CD34+ HSCs), 18Lin-CD34-CD133+GPI-80+ cells (CD34- HSCs) and 18Lin-CD34+CD133- cells (non-HSCs) were analyzed. Results provide an insight into the molecular mechanisms underlying the self-renewal, maintenance and differentiation of human cord blood-derived CD34+/- HSCs.

2017-06-23 | GSE100354 | GEO

Primary human CD34+ cells for modeling ETO2-GLIS2 leukemogenesis - Bulk RNAseq

Project description:Several fusion oncogenes showing a higher incidence in pediatric acute myeloid leukemia are associated with heterogeneous megakaryoblastic and other myeloid features. Here we addressed how developmental mechanisms influence human leukemogenesis by ETO2::GLIS2, a hallmark of dismal prognosis. We induced expression of ETO2::GLIS2 in primary human fetal and cord blood CD34+ hematopoietic cells and obtained bulk transcriptomes after in vitro cultures or in vivo engraftment and leukemia development in immunodeficient recipients (NSG or NSG-SGM3=NSG-S).

2024-10-08 | E-MTAB-14131 | biostudies-arrayexpress

RNA sequencing of ETV6-NCOA2 expression in CD34 positive cord blood cells

Project description:Mixed-phenotype acute leukemia is a rare subtype of leukemia in which both myeloid and lymphoid markers are co-expressed on the same malignant cells. Their pathogenesis is largely unknown, and their treatment is challenging. We have previously discovered the specific association between recurrent t(8;12)(q13;p13) chromosomal translocation, creating ETV6-NCOA2 fusion, with T/Myeloid leukemias. Here we report that the ETV6-NCOA2 initiates T/Myeloid leukemia in preclinical models and examine the expression profile induced by ETV6-NCOA2 in CD34+ cord blood progenitors in-vitro.

2022-05-16 | GSE162230 | GEO

CD34 is a drug target for AML and CML

Project description:EGFR inhibitors selectively kill CD34+ leukemia cells and induced clinical remission in patients with high percentage of CD34+ blast

2020-12-30 | PXD023328 |

Epigenetic and molecular signatures of cord blood CD34(+) cells treated with histone deacetylase inhibitors

Project description:Gene expression profiling of primary cord blood hematopoietic stem cell (day 0, CD34+ cells), enriched control (untreated), Scriptaid and Valproic acid expanded CD34+ cells after a week in culture. Cord blood CD34+ cells were processed individually and equal number of PC and reisolated CD34+ cells from 3-4 samples were pooled after expansion to avoid sample variations.

2014-07-29 | GSE59803 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data